Macquarie Group’s Lunai Bioworks LNAI Stock Holding History

Macquarie Group’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-63	Closed	-$13	–	2084
2024 Q1	$13	Buy	+63	New	+$17K	﹤0.01%	1713

Other funds holding LNAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Macquarie Group's LNAI Position: Q2 2024 in Review

Macquarie Group sold out of Lunai Bioworks (LNAI) in Q2 2024, closing a stake of 63 shares — an estimated $13 sold.

Macquarie Group first reported a position in LNAI in Q1 2024 and held it in 1 quarter. The position peaked at $13 in Q1 2024. 39 funds tracked by Wall St. Rank hold LNAI as of Q2 2024.

Macquarie Group reported no remaining Lunai Bioworks position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 63 Lunai Bioworks shares in Q2 2024, an estimated $13.
Macquarie Group first reported a position in Lunai Bioworks in Q1 2024 and held it in 1 quarter.
Macquarie Group's Lunai Bioworks position peaked at $13 in Q1 2024.
39 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.